Medical Oncologist
CION Cancer Clinics
Y-90 as a bridge to transplant or surgery: who it is for | CION Cancer Clinics
Y-90 can be used to hold a liver cancer in check while you wait for a transplant, or to shrink it until surgery becomes possible. It suits some people with primary liver cancer whose disease is confined to the liver and whose liver still works well. This page explains how the team decides, what happens step by step, and who it does not suit. At CION Cancer Clinics, a multidisciplinary tumour board weighs your liver function and your scans before recommending any treatment.
MM
Medically reviewed by Dr. Muralidhar MuddusettyConsultant Surgical Oncologist · MBBS (AIIMS), MS (Surgery, AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh) · last reviewed October 2026, next review due October 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What does it mean to use Y-90 as a bridge?
- How does the team decide whether Y-90 can bridge you?
- What happens from the first meeting to surgery or transplant?
- How does Y-90 compare with other bridges?
- Who is Y-90 bridging not right for?
- What this page cannot tell you
- Common questions about Y-90 as a bridge
The short answer
What does it mean to use Y-90 as a bridge?
Y-90 as a bridge means using radioembolisation to hold a liver cancer in check, or shrink it, while you wait for a transplant or an operation. It is for people with primary liver cancer (hepatocellular carcinoma, or HCC) whose tumour is in the liver only and whose liver is still working reasonably well.
Two different jobs with one treatment
Doctors use the word bridging when you already qualify for a transplant and the aim is to stop the tumour growing past the limits while you wait for a donor liver. They use the word downstaging when the tumour is currently too large or too many, and the aim is to shrink it until a transplant or a resection becomes possible. Our page on downstaging explains that idea in full.
How Y-90 does it
Y-90, also called TARE (transarterial radioembolisation), sends tiny beads carrying radiation into the artery that feeds the tumour. The radiation works from inside the tumour over the following weeks. The technique itself is covered on our Y-90 radioembolisation page. This page is about the decision.
If your report says liver metastases, meaning cancer that spread to the liver from another organ, this page is not about you. Read Y-90 for liver metastases instead.What the team weighs
How does the team decide whether Y-90 can bridge you?
No single test answers this. The tumour board looks at three things together, and all three have to line up.
The tumour
Its size, how many there are, and whether it has grown into the portal vein, the main vein bringing blood into the liver. A tumour that has already spread outside the liver is not a bridging case.
Things that help
- Disease confined to the liver
- A tumour fed by a clear artery
- One side of the liver mostly affected
The liver itself
Blood tests such as bilirubin (the yellow pigment that causes jaundice) and albumin (a protein the liver makes) show how much reserve is left. The Child-Pugh score bundles these into one grade. A liver with little reserve may not tolerate radiation.
You as a person
How active you are, your heart and lungs, and whether you could safely go through a transplant or a major operation later. Bridging only makes sense if the destination is realistic.
Why Y-90 rather than TACE
TACE (chemoembolisation) is the more common bridge. Y-90 is often preferred when the tumour is large, when the portal vein is partly involved, or when the team wants to shrink one side of the liver. Our comparison with TACE sets these out.
Not sure whether this applies to you?
Ask an oncologistThe path
What happens from the first meeting to surgery or transplant?
Review by the tumour board
Your scans, blood tests and history are discussed by medical, surgical and radiation oncologists together. If a transplant is the goal, a licensed transplant centre is involved from the start.
The mapping scan
An interventional radiologist at a partner hospital maps the liver arteries and checks how much would leak to the lungs. This decides whether Y-90 is safe at all. See the mapping scan.
The Y-90 treatment
CION coordinates the treatment through accredited partner hospitals that hold the licence to handle the radioactive beads. Most people go home the same day or the next.
Scans to measure the response
Follow-up scans show whether the tumour has stayed within limits or shrunk. The effect builds slowly, so an early scan can look unchanged. Your team sets the timing.
The next decision
If the tumour is controlled, you stay on the waiting list or move on to resection. If it keeps growing despite treatment, the team rethinks the plan honestly with you.
Side by side
How does Y-90 compare with other bridges?
Y-90 (TARE)
The usual alternatives
Usually one treatment, sometimes two
TACE is often repeated several times
Can be used with some portal vein involvement
TACE is often not safe when the portal vein is blocked
Can shrink one side so the other side grows
Portal vein embolisation does this without treating the tumour
Needs a mapping scan and a licensed centre
Ablation and TACE are more widely available
Usually costs more and is quoted separately
TACE and ablation have more predictable costs
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Being honest
Who is Y-90 bridging not right for?
Y-90 bridging does not suit everyone with HCC, and it is better to know that early. It is usually not offered when the cancer has spread outside the liver, because then neither transplant nor resection is the goal. It is also not offered when the liver is failing, with deep jaundice or fluid in the abdomen (ascites) that is hard to control.
When the mapping scan says no
If too much of the dose would travel to the lungs, or the arteries would carry beads to the stomach or bowel, the treatment is not safe. Our page on lung shunting explains why.
When the destination is not realistic
A bridge needs somewhere to go. If you are not fit for a transplant or a major operation, the team may still use Y-90, but to control the cancer, not as a bridge. If your tumour is small enough for ablation or surgery straight away, waiting for Y-90 may only add delay.
Not being suitable for a bridge is not the end of treatment. Tablets, immunotherapy and other options remain.Being straight with you
What this page cannot tell you
It cannot tell you whether you will reach a transplant or surgery. Some people are bridged successfully. Others see the tumour grow despite treatment, or their liver weakens. Nobody can predict that from a web page, and the evidence comparing Y-90 with TACE as a bridge is still limited.
It cannot place you on a waiting list
Transplant listing and priority are decided by the transplant centre under rules set by Jeevandan in Telangana and national bodies. As of 2026 those rules change from time to time and must be checked with the transplant centre. CION cannot influence your place on any list.
It cannot give you a price
Y-90 is not offered in every Indian city, and the cost is quoted separately by the centre that does it. Ask for a written, itemised estimate that includes the mapping scan. Our page on where Y-90 is available covers access.
Bring your latest scan and blood reports to a consultation. The tumour board can tell you whether bridging is worth discussing.Questions we are asked
Common questions about Y-90 as a bridge
Can Y-90 on its own remove liver cancer for good?
Usually not. On its own, Y-90 is mostly used to control or shrink a tumour. When it works as a bridge, the curative step is the transplant or the operation that follows. Some people are not able to reach that step, and your team will be honest about where you stand.
Is Y-90 better than TACE as a bridge?
Neither suits everyone. TACE is more widely available and has longer experience behind it. Y-90 may suit larger tumours, some portal vein involvement, or plans to grow one side of the liver. The tumour board weighs your scans and liver function before suggesting one.
Does CION do Y-90 itself?
No. CION's oncologists assess you, present your case at the tumour board and plan the treatment. The mapping scan and the Y-90 procedure are coordinated through accredited partner hospitals with interventional radiology and a licence to handle the radioactive beads.
How soon does Y-90 shrink the tumour?
Slowly. The radiation keeps working for some time after the procedure, and the tumour may look the same or even slightly larger on an early scan before it shrinks. Your team will decide when the scan is most useful and will not judge the result too early.
Can I still have a transplant after Y-90?
Yes, if the tumour stays within the limits the transplant centre uses and your liver and general health remain good enough. Y-90 does not rule out a later transplant. The transplant team decides eligibility, not the team that gave the bridge.
What if the tumour grows despite Y-90?
Then the team reviews the plan. A tumour that grows quickly through a bridge can be a sign it would come back after a transplant too. Other options, such as tablets or immunotherapy, may then be the better path, and the reasons will be explained.
Will Aarogyasri or insurance pay for Y-90?
It depends on the scheme, the policy and the centre, and the rules change. Ask the treating hospital's insurance desk before the mapping scan. This is general information, not advice on your policy. CION's team can help you with the scheme paperwork.
Where should I start?
Gather your latest triple-phase CT or MRI, your blood reports and any biopsy result. Call the CION helpline and ask for a tumour board review. If transplant is already being discussed, bring the transplant centre's letters too, so both teams work from the same picture.
Your Specialists
Meet CION's liver cancer specialists. Bring your scan reports and liver blood tests.
Our medical and surgical oncologists plan liver cancer care together, weighing the tumour and how well your liver works before choosing surgery, a liver-directed procedure or medicines.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- RadiologyInfo.org (RSNA/ACR) — Radioembolization (Y90)
- American Cancer Society — Embolization Therapy for Liver Cancer
- NIDDK — Liver Transplant - NIDDK
- RadiologyInfo.org (RSNA/ACR) — Management of liver cancer (ACR Appropriateness Criteria, patient summary)
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Bridging therapy while waiting for a transplantAll the bridge options, not only Y-90Downstaging to become transplant-eligibleWhen the tumour is too big for the list todayRadiation lobectomyUsing Y-90 to grow the healthy side before surgeryWho is suitable for Y-90?The checks that come before any bridge
Talk to us
Is a bridge to transplant or surgery possible for me?
Send us your latest scan and blood reports and the tumour board will review whether bridging or downstaging is worth discussing. We will tell you plainly if it is not. One helpline serves every CION centre.